|
|
 |
|
Viewing report
|
|
|
|
The Cardiovascular Market Outlook to 2009
Business Insights, Oct 2004
'The Cardiovascular Market Outlook to 2009' is a report which provides detailed analysis on the major cardiovascular therapy areas and assesses competitive dynamics over the period 2004 to 2009. This report provides essential data, analysis and forecasts allowing you to position your products effectively, maximize market opportunities and increase cardiovascular revenues.
The cardiovascular market is set to undergo a period of radical change, as today's blockbusters lose patent protection. The pharmaceutical industry is embracing innovative new technologies in order to provide the products of tomorrow, but with high costs and risks associated with the development of new medicines in this area, there will be fewer winners than losers in the future.
Use this analysis to identify the forthcoming issues affecting cardiovascular markets, drugs, and companies and gain insight into the forces driving the most valuable sector of the pharmaceutical industry over the next 5 years.
Why you should order your copy today
- Assess the strength of leading players’ cardiovascular portfolios and identify how they are positioning themselves to maintain and build franchise revenues.
- Analyze the recent performance of drugs in each therapeutic class of the global cardiovascular market.
- Quantify your products’ market potential in the cardiovascular market by evaluating the patient base in different therapeutic classes.
- Understand how the competitive landscape may be changed by the result of clinical trials such as EUROPA, EPHESUS, COMET and CHARM.
- Identify the market potential and risks related to a range innovative future cardiovascular drugs currently in development, and assess their impact on the pipelines of the major players in the cardiovascular area.
'The key driver of sales growth in the hypertension market is the ARB class, sales of which expanded by 27.7% to $8,971m in 2003. ARBs continue to be the only class of hypertension treatments that is unaffected by generic competition and can command a higher price premium than most rival products. Despite the presence of generic competition, alpha-blockers, beta-blockers and diuretics continued a pattern of modest growth in 2003, find out more with the help of this new report…'
'The late to market status of Livalo has jeopardized rapid uptake in the major markets, and doubt now exists about whether this statin, which is relatively undifferentiated from rivals, can create a niche for itself in the absence of major marketing backing in the US...'
Key findings of the report
- Pfizer’s growth will be adversely affected by the continuing disappointing performance of recent launches Inspra and Caduet as well as the expiry of patents protecting Norvasc.
- The net revenue growth of the cardiovascular franchises of the major players are set to suffer a net contraction in revenue growth, with Aventis and Pfizer performing particularly poorly over the forecast period 2004 to 2009.
- Despite increasing prescribing volumes, earlier interventions and robust epidemiological growth, market growth across the major indications is set to fall over the forecast period.
- Over the short-term, thrombosis is set to be the major driver in the cardiovascular area, whilst heart failure has the most favorable dynamics of any indication for rapid market growth.
- The growth of the dyslipidemia market is set to be further fuelled by statin adjunct therapies, particularly Zetia, which is forecast to revive Merck's faltering cardiovascular franchise.
'New launches Crestor and Livalo have little hope of attaining sales on the scale of Lipitor, which, following concerns about safety after the withdrawal of Baycol in 2001, has successfully distanced itself from dose dependent side-effects. Crestor, partly due to alleged negative marketing strategies from Pfizer, has failed to distance itself from these safety concerns, evident in its disappointing start following its launch in 2003...'
The answers to your questions
- How have recent major cardiovascular drug launches from Pfizer, AstraZeneca, Novartis, Merck, Aventis and BMS performed?
- Which companies will become the key players in the cardiovascular market over the period 2004-2009?
- Which pipeline products will be the growth drivers of the future?
- Which products will be impacted by generic competitors over the period 2004-2009?
- Which indications are forecast to have the highest levels of market potential in the forecast period?
- How will the competitive landscape for hypertension, thrombosis, dyslipidemia and arrhythmia change by 2009?
'In terms of sales growth, Merck lagged behind other major players, a culmination of stiff generic competition and a lag in replacing key products. Merck's cardiovascular franchise is currently at a nadir but forecast for recovery. The most significant contributor to Novartis’ stellar rate of sales growth is largely a product of Diovan’s success. Diovan is poised to become the class leader in 2004...'
'Analysis of recently launched compounds and the most promising compounds in late stage development show that pharmaceuticals are developing innovative responses to what are now saturated and cluttered traditional markets in hypertension and dyslipidemia. The late stage development pipelines of pharmaceuticals are innovative, some of which have the potential to reengineer currently prevailing treatment paradigm...'
Customers who bought this item also bought
The Cardiovascular Disorders Market Outlook to 2012
Cardiovascular Drug Discoveries 2008
The Cardiovascular Market Outlook to 2013: Competitive Landscape, Global Market Analysis and Pipeline Analysis
The Cardiovascular Market Outlook to 2008
The Cardiovascular Market Outlook to 2011
The Cardiovascular Market Outlook to 2010
The Asian Cardiovascular Market Outlook to 2014: Regional and Therapeutic Analysis, Pipeline Impact and Growth Opportunities
Cardiovascular Drug Delivery - Technologies, Markets and Companies
The Asian Cardiovascular Market Outlook to 2010
The Cardiovascular Outlook to 2007
The Latin American Cardiovascular Market Outlook to 2010
The Eastern European Cardiovascular Market Outlook to 2010
|
|
|
|
